Are Peptides Safe for Teens? What Parents Should Know

Why This Question Matters

Peptide therapy has grown rapidly in adult clinical practice. GH-axis peptides, healing peptides, and metabolic compounds have found a significant audience among adults seeking performance, recovery, and longevity benefits. As their visibility has grown, questions about adolescent use have followed. Some come from parents concerned about a teen's athletic performance or body composition. Some come from teens who have encountered peptides through fitness communities or social media. The question deserves a careful, evidence-based answer.

The short version is that no investigational peptide therapy designed for adult systemic use (GH secretagogues, BPC-157, cognitive peptides) has established safety data in adolescent populations — FDA-approved rhGH has pediatric safety data for specific approved indications only — and the biology of adolescence introduces specific risks that do not apply to adults. Understanding those risks requires understanding what puberty actually does to the systems that injectable peptides target.

The Adolescent GH/IGF-1 Axis: Why It Is Different from Adults

Adult peptide therapy targeting the growth hormone axis is developed for a specific biological context: adults whose GH secretion has declined from its youthful peak, whose IGF-1 levels have fallen, and whose pituitary responsiveness to secretagogue stimulation has diminished. The entire rationale for GH secretagogue therapy — compounds like ipamorelin, CJC-1295, sermorelin, and tesamorelin — is that adult GH pulsatility is suppressed relative to adolescence, and that restoring a more youthful GH pattern produces measurable metabolic and body-composition benefits.

Adolescents are, by definition, not in that state. Torres-Santiago and Mauras, in a 2024 clinical review in the Journal of Clinical Endocrinology and Metabolism, described how sex steroids drive growth-plate closure in puberty — mediated primarily via estrogen receptor α in both males and females — constraining the biological window in which the GH axis acts on the growing skeleton. Olarescu and colleagues, in a chapter of the Endotext endocrinology reference, document the normal physiology of growth hormone in adults, which provides the mechanistic rationale for GH secretagogue therapy in adults but suggests it would be redundant or produce supraphysiologic effects in adolescents, an outcome that has not been studied in controlled trials.

Adding exogenous GH secretagogues in this context does not augment a deficient system. It stimulates an already-maximally-active one — with consequences that are not predictable and have not been studied.

Growth Plate Risk: The Biological Core of the Concern

What growth plates are and why they matter

Growth plates (epiphyseal plates) are regions of cartilaginous tissue at the ends of long bones that contain actively dividing chondrocytes and stem cells responsible for bone elongation. They are the anatomical structures that determine final adult height. During childhood and adolescence, they remain open — a window of active skeletal construction. They close in response to rising sex hormones during and after puberty, typically completing closure by the late teens to early twenties. Until closure, they are biologically active and structurally vulnerable in ways that post-adolescent bone is not.

GH directly regulates growth plate stem cells

Chu and colleagues, publishing in Science Translational Medicine in 2026, produced a transcriptional atlas of the pubertal human growth plate and demonstrated GH regulates growth plate stem cells — specifically two stem cell populations within the actively growing adolescent growth plate. In a companion paper in PNAS (2025), the same group demonstrated that GH regulates growth plate stem cells — establishing mechanistically that GH-axis stimulation can alter the cellular dynamics of this tissue. The implication is direct: a GH secretagogue that amplifies GH secretion during adolescence is not acting on a passive bystander tissue — it is intervening in an active, coordinately regulated stem cell process that drives skeletal development.

Known risks from approved GH therapy in pediatric patients

The risks associated with GH-axis manipulation in adolescents are not theoretical constructs drawn from first principles. They are documented in the literature on FDA-approved recombinant GH therapy used in children with diagnosed growth failure. Zverev and colleagues, in a 2024 review in Children (Basel), documented that pediatric GH therapy carries orthopedic risks including slipped capital femoral epiphysis and scoliosis progression — adverse events that arise specifically from the interaction between exogenous GH and the actively growing skeleton. A systematic review and meta-analysis by Bin-Abbas and colleagues, published in the Journal of Clinical Medicine in 2025, further documented the adverse event profile of GH therapy in children, concluding that even standard, carefully supervised GH therapy requires ongoing monitoring for adverse effects. Juul and colleagues, reporting 4-year data from a once-weekly GH analog study in children published in the European Journal of Endocrinology in 2026, confirmed that approved pediatric GH therapy requires long-term monitoring.

If adverse events are documented with carefully prescribed, pharmaceutical-grade, licensed-product GH therapy supervised by pediatric endocrinologists in children with diagnosed deficiency — the risk profile of unsupervised, unregulated GH secretagogue use in healthy adolescents is considerably more concerning.

IGF-1 Elevation in Adolescence: A Specific Concern

GH secretagogues work primarily by stimulating GH release, which in turn drives IGF-1 production in the liver. Elevated IGF-1 is the measurable downstream signal of GH axis activation, and it is the marker most closely tracked in patients on GH-axis therapies.

In adults with low IGF-1 from age-related GH decline, restoring IGF-1 toward a more youthful range is a stated clinical goal. In adolescents, IGF-1 is already at its lifetime peak. Papadimitriou and colleagues, in a 2022 review in Trends in Endocrinology and Metabolism, reviewed how IGF-1 regulates pubertal timing and growth pattern variations, with early GH/IGF-1 axis activation driving the pattern of constitutional advancement of growth and puberty.

Burgers and colleagues conducted a meta-analysis of circulating IGF-1 and mortality published in the Journal of Clinical Endocrinology and Metabolism in 2011 and demonstrated that elevated IGF-1 is associated with cancer mortality across large population samples. Dhaneshwar and colleagues, writing in Endocrine, Metabolic and Immune Disorders Drug Targets in 2023, reviewed multi-system consequences of GH/IGF-1 excess in acromegaly — including cardiovascular, cerebrovascular, and pulmonary dysfunction — illustrating the systemic burden of sustained supraphysiologic GH exposure. In adolescents, where IGF-1 is already elevated and rapidly proliferating tissues are present throughout the skeleton, adding additional GH axis stimulation introduces risk without any established clinical benefit.

GH Secretagogues and the Pubertal Axis: Synergistic Amplification

A specific pharmacological concern involves the synergistic relationship between GHRH-class peptides and GHRP-class peptides. Veldhuis and Bowers, in a study of 47 adult men published in the American Journal of Physiology — Endocrinology and Metabolism in 2009, demonstrated that GHRH and GHRP synergistically amplify GH pulses that exceeds the sum of each stimulus individually. Whether the same synergistic mechanism produces supraphysiologic GH amplitudes in adolescents with already-active endogenous GH secretion has not been tested in controlled trials; the concern is mechanistic, not demonstrated in pubertal humans. The consequences of sustained supraphysiologic GH exposure in actively growing tissues — including the growth plate stem cell populations documented by Chu and colleagues — are unstudied and unpredictable.

The Body Composition Argument: Why the Mechanism Does Not Apply

One common rationale for GH secretagogue use in adults is body composition: reducing fat mass and preserving lean mass. Kempf and colleagues, in a 2022 paper in Adipocyte, documented adipose GH receptor and IGF-1 alterations in obesity-related changes in children — describing a disrupted-signaling pattern in the direction of deficiency, not excess. A healthy adolescent's GH axis is already producing body composition changes appropriate to their developmental stage. There is no clinical rationale for augmenting a non-deficient axis in a growing person.

Peptides Beyond GH Secretagogues: The Absence of Pediatric Data

BPC-157 and healing peptides

BPC-157, often discussed in the context of tissue repair and recovery, is frequently mentioned as a "gentle" or "low-risk" peptide compared to GH-axis compounds. This framing is inaccurate. McGuire and colleagues, in their 2025 review in Current Reviews in Musculoskeletal Medicine, confirmed that BPC-157 has been studied exclusively in adult and animal contexts with no pediatric safety data. Sikiric and colleagues, writing in Pharmaceuticals in 2026, documented BPC-157's vascular cytoprotective actions in preclinical (animal-model) hemorrhage and thrombosis contexts, including reported effects on endothelial integrity and hemostasis in those models. In an adolescent with developing organ systems, these systemic effects are not predictable. No safety data exists, and the absence of data is not the same as safety.

Cognitive peptides

Semax and selank are not FDA-approved for any indication in the U.S. They are primarily distributed internationally and domestically as "Research Use Only" products, which are not intended for human administration. Vanhee and colleagues, in a 2020 paper in Drug Testing and Analysis, documented that cognitive-enhancing peptides including semax and selank are found in seized preparations with quality concerns and documented authenticity issues. There is no clinical evidence supporting the safety or efficacy of these compounds in adolescents, and the sourcing risks are the same as for other peptide classes.

Product Sourcing Risk: A Compounding Factor for Teens

Adults who access peptide therapy through a licensed provider under a valid prescription — where the specific peptide is an FDA-approved drug product, or is one of the narrow set of peptides lawfully compoundable under current 503A/503B rules — are in a different regulatory position from teens obtaining peptides independently through online grey-market vendors, social media, or supplement channels. Compounding does not equal FDA approval. Many peptides discussed in teen fitness communities (including BPC-157, TB-500, and most GH secretagogues) are not currently available through lawful compounding pharmacies under 2026 FDA rules following the February 2026 Pharmacy Compounding Advisory Committee determinations. Where compounding is available, compounded preparations are produced by state-licensed 503A pharmacies (or 503B outsourcing facilities where applicable) from bulk drug substances meeting USP/NF or equivalent quality standards where required.

Krug and colleagues, in their 2018 analysis of black-market growth-promoting peptide products in Growth Hormone and IGF Research, documented contamination and systematic mislabeling in products sold outside licensed pharmacy channels — including products that contained different compounds than labeled. Gajda and colleagues, in a 2019 paper in Drug Testing and Analysis, documented unlisted GH secretagogue analogs in seized doping products, meaning a teen may be injecting a compound they cannot identify from a vendor with no accountability. Gudeman and colleagues (2013) reviewed quality and sterility risks in pharmacy compounding, noting that compounded preparations are not subject to the premarket FDA safety/efficacy evaluation required of approved drugs — and that these risks are materially greater when compounds are sourced outside any pharmacy framework (i.e., from online research-chemical vendors). Compounded peptides are not FDA-approved or equivalent to approved drug products; compounding is a pharmacy practice, not a product-level regulatory approval, and under 21 U.S.C. § 353a(b)(2) 503A pharmacies generally cannot compound "essentially a copy" of an FDA-approved drug absent a documented clinical difference.

Additionally, bacteriostatic water (BAC water) — commonly used to reconstitute injectable peptide preparations obtained outside an FDA-approved, provider-dispensed kit — contains benzyl alcohol as its preservative. Gershanik and colleagues, in a 1982 paper in the New England Journal of Medicine, documented that benzyl alcohol in preserved injections is contraindicated in neonates ("gasping syndrome"). Benzyl alcohol's pediatric safety profile in adolescents specifically is not well characterized, and preservative-containing injectable preparations outside a pediatric-approved product have not been evaluated for this age group.

Teen Athletes: Anti-Doping Risk Compounds the Biological Risk

For teen athletes in organized competition, peptide use carries an additional consequence that is often underappreciated. Multiple peptide classes — including GH secretagogues, GH itself, and related compounds — are prohibited by the World Anti-Doping Agency (WADA). Thomas and colleagues, writing in Drug Testing and Analysis in 2023, confirmed that insulin-mimetic peptides are detectable in sport anti-doping testing using LC-HRMS/MS methods, and that WADA-prohibited peptide classes can be identified in athlete samples and can result in disqualification from high school and collegiate athletic competition. A teen athlete who uses a peptide compound for recovery or performance enhancement risks not only the biological consequences described above but also the invalidation of competitive results and potential multi-year suspension from sport.

What Parents Should Actually Do

If a teenager is asking about peptides, the most useful response is to take the underlying concern seriously rather than dismiss it, while redirecting toward evidence-based clinical evaluation. Most concerns that drive teens toward peptide research — fatigue, body composition, slow recovery, low energy — have identifiable biological explanations that appear in standard bloodwork.

A baseline evaluation that includes iron status, vitamin D, thyroid function (TSH, free T3, free T4), sex hormone levels appropriate for pubertal stage, IGF-1, and basic metabolic markers including fasting glucose and HbA1c provides objective context for the teenager's biology. Many of the symptoms that drive peptide research in healthy young people are attributable to iron deficiency, vitamin D insufficiency, or sleep disruption — all of which respond to evidence-based interventions without the risks of injectable hormone-axis manipulation.

A pediatrician or adolescent medicine physician is the appropriate starting point. For any concern involving growth velocity, pubertal timing, or body composition at an endocrine level, a referral to a pediatric endocrinologist is the appropriate pathway — not peptide sourcing.

Understanding Your Baseline Before Any Intervention

For families considering any biological intervention for a teenager — whether a supplement, a prescribed medication, or an investigational compound — the principle that objective data should precede action applies directly. Before any conversation about what to do, a baseline panel that reflects the GH axis, metabolic status, and nutritional markers provides the foundation for a clinically grounded discussion with a licensed provider.

Reviewing a teenager's IGF-1 levels alongside metabolic markers gives any clinician the reference points needed to determine whether a concern about growth, body composition, or energy is explained by objective biology. Pediatric biomarker testing should be ordered through a pediatrician or pediatric endocrinologist; Superpower biomarker testing is available only to adults. That principle — understanding biology through measurement before acting on it — is foundational to Superpower's approach to preventive health: biomarker data first, clinical decisions second, with a licensed provider involved at every step.

Important Safety Information

This page is provided for educational and informational purposes only. No injectable peptide therapy designed for adult systemic use (such as GH secretagogues, BPC-157, or cognitive peptides) has established safety data in adolescent populations. FDA-approved recombinant GH has pediatric safety data only for specific approved pediatric indications. The investigational peptide therapies discussed on this page (GH secretagogues, BPC-157, semax, selank) are not FDA-approved for any pediatric use and should not be used by minors outside an IRB-approved clinical research study. FDA-approved recombinant GH has specific pediatric indications and should be used only under pediatric endocrinologist supervision.

The GH/IGF-1 axis is maximally active during puberty. Exogenous stimulation of GH secretion during adolescence may alter growth plate development, produce supraphysiologic IGF-1 elevation, and interact with actively ossifying skeletal structures in ways that are not fully characterized. Growth plate changes from exogenous GH-axis manipulation during adolescence become anatomically fixed once growth plates have closed; premature closure is not reversible.

Products sold as peptides through online vendors are not regulated for safety, purity, or potency by the FDA. Gray-market injectable products have documented contamination, mislabeling, and adulteration. A teen injecting a product from an unregulated online source cannot verify its contents. Benzyl alcohol (the preservative in bacteriostatic water commonly used to reconstitute injectable peptides) carries documented risks in neonates and is not characterized for adolescents; its pediatric-specific safety profile is not established in this age group.

Multiple peptide classes are prohibited by the World Anti-Doping Agency (WADA). Teen athletes subject to anti-doping testing who use prohibited peptides risk disqualification, suspension, and invalidation of competition results.

For concerns about growth, body composition, energy, or athletic performance in adolescents, consult a pediatrician or pediatric endocrinologist. A baseline blood panel provides objective context for any clinical evaluation. Superpower Health does not offer peptide services to adolescents.